Efficacy of Talquetamab Plus Teclistamab in Patients with Extramedullary Myeloma By Ogkologos - December 10, 2025 411 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the phase II cohort of the RedirecTT-1 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Combination Therapy for Metastatic Prostate Cancer Helps Some Men Live Longer March 11, 2025 First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 Patients With DCIS Reduce Risk Of Recurrence And Death If They... June 25, 2020 A Phase III Study of Spartalizumab in Combination with Dabrafenib and... January 20, 2022 Load more HOT NEWS Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... Searching for novel connections in cancer metabolism What to Expect During a Skin Cancer Screening
